Navicent Corporate Integrity Agreement

13 Déc Navicent Corporate Integrity Agreement

G.F. « Pete » Peterman, III, United States Attorney for the Middle District of Georgia, and Georgia Attorney General Christopher M. Carr today announced a civil agreement with Central Georgia Medical Center, Inc., d/b/a The Medical Center, Navicent Health (« Navicent Health »). Navicent agreed to pay $2,549,742 in the United States and the State of Georgia to clarify charges that it violated the False Claims Act and the Georgia False Medica Claims Act by filing invoices for the transportation of ambulances that were either excessive or medically unnecessary. In addition, Navicent`s current Enterprise Integrity Agreement (CIA) is being expanded and extended to newly dissolved behaviors. A CIA is an agreement between a private provider and the United States, under which the supplier introduces and maintains, at its own expense, an OIG-controlled program, with audits by an independent monitoring body, to ensure compliance with the laws and rules relating to participation in state-funded programs. As part of this agreement, MCCG entered into an enterprise integrity agreement with the U.S. Department of Health and Human Services – Office of Inspector General (HHS-OIG), which requires the company to make significant compliance efforts over the next five years. Under the agreement, MCCG is required to maintain an independent audit body to verify the accuracy of the company`s rights to services provided to recipients of the state public health program. Along with the payment of the FCA fees, Novartis entered into an Enterprise Integrity Agreement (CIA) with the Department of Health and Human Services Office of Inspector General (HHS-OIG).

Among other things, the CIA requires Novartis to significantly reduce its paid speaker programs and the amount spent on programs. In addition, all remaining speaker programs may only occur in limited circumstances (which may only be available within 18 months of FDA approval of a new state reimbursement product or a new indication of a national reimbursement product previously authorized by the FDA) and in a virtual format (external speakers must be remote and not in the same location as a member of the public). In addition, there is a cap of $100,000 in total compensation for speech and spokesperson training and a total salary cap of $10,000 per spokesperson (without direct payment by Novartis for travel and travel expenses). Mr. Valentine will receive some of the compensation. The case did not have the effect of liability. As part of the comparison, Navicent agreed to pay more than $2.5 million to refute accusations that they submitted ambulance bills « either excessive or medically unnecessary, » the statement said. Prosecutors argued that Navicent violated the Federal False Claims Act and the Georgia False MedicaId Claims Act by filing the bills. Thomas Sullivan is Editor-in-Chief of Policy and Medicine, President of the Rockpointe Corporation, established in 1995 to provide ongoing medical training to healthcare professionals around the world. Prior to Rockpointe`s creation, Thomas worked as a political advisor. Oncologist sentenced to one year, one day for the theft of government funds Then, in the second count, Novartis will pay $591.4 million, to solve the charges of false Claims Act (FCA) that paid kickbacks to prescribe doctors to prescribe several Novartis drugs, including Lotrel, Valturna, Starlix, Tekturna, Tekturna HCT, Tekamlo, Diovan, Even in this comparison, Novartis loses $38.4 million under the Civil Asset Forfeit Statute.

According to the U.S. Attorney`s Office, the investigation revealed two alleged plans.